Activist Shareholders and Regulatory Changes Undermining Corporate Control

American corporate boards are facing a period of diminished control as they contend with a combination of regulatory changes and increasing pressure from activist shareholders.

According to reporting by The Economist on April 14, 2026, these factors are actively undermining the traditional authority of corporate boards in the United States.

The Mechanics of Shareholder Activism

Shareholder activism occurs when investors use their equity stakes in a corporation to exert pressure on management. This process does not always require a majority stake; a position of less than 10% of outstanding shares can be sufficient to launch a successful campaign.

The objectives of these activists vary between financial and non-financial goals. Financial objectives typically focus on increasing shareholder value through cost-cutting measures or changes in corporate policy. Non-financial goals may include demands for disinvestment from specific countries.

Activists employ several different tactics to achieve these ends, including:

• Proxy battles
• Publicity campaigns
• Shareholder resolutions
• Litigation
• Direct negotiations with corporate management

These campaigns are often designed to address the principal-agent problem, where corporate management (the agents) fails to respond adequately to the wishes of the investors (the principals).

Regulatory Shifts and Board Composition

Changes in regulation have further shifted the balance of power. The universal proxy card rules, which took effect in 2022, have simplified the process for activists to target long-tenured directors.

Data from 2024 indicates a robust environment for shareholder activism in the U.S., characterized by a level of activity not previously seen. Activists have successfully pushed for the replacement of long-tenured directors with new, independent board members to improve corporate accountability, transparency, and performance.

The decision to target a specific company is generally driven by the activist’s belief in a narrative of significant shareholder value creation. However, the emergence of inexperienced activists who do not follow established playbooks has created additional difficulties for companies.

Impact on Innovation and Corporate Science

The pressure exerted by activist investors can have long-term implications for corporate research and development. Research conducted by Professor Elia Ferracuti of Duke University’s Fuqua School of Business, along with Rahul Vashishtha and Kevin Standbridge, suggests that hedge-fund-led activism can undermine breakthrough science.

The study found that after being targeted by activist hedge funds, firms produce significantly less scientific research. This decline is most pronounced in publications within top-tier academic journals.

In the pharmaceutical sector, the research observed a specific shift in innovation strategy. Targeted firms moved away from the development of novel drugs in favor of incremental me-too compounds that closely resemble existing treatments.

Activism pushes corporations away from risky activities with long gestation periods and large spillovers.

Professor Elia Ferracuti

This tension highlights a conflict between the short-term financial pressures demanded by activists and the long-term requirements of scientific progress and basic research.

Broader Market Influence

The influence of activism extends to major corporate transactions. A 2015 survey of corporate development leaders revealed that 60% of respondents believed shareholder activism was affecting transaction activity within their respective industries.

While some activists use adversarial campaigns, others have managed to secure formal board seats through proxy contexts. This ongoing trend continues to reshape corporate governance and the way companies engage with their broader shareholder base.